Strikingly, the seizure phenotypes and survival of Scn1a mutant mouse models of Dravet syndrome and GEFS+ can be dramatically improved by the co-expression of a heterozygous Scn8a loss-of-function allele4,7. Here, SCN1A is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.